PDCD1 and non-small cell squamous lung carcinoma: For example, the antibody-mediated blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) were recently approved by the US FDA in the treatment of patients with advanced melanoma [11] and squamous non-small cell lung cancer [12].